Diabetic Nephropathy Market 2027 by Indication, Treatment Type, Diagnosis, End User , and Geography | The Insight Partners

Diabetic Nephropathy Market Forecast to 2027 - Covid-19 Impact and Global Analysis - By Indication ( Type-1 Diabetes, Type-2 Diabetes ); Treatment Type ( Diuretics, Angiotensin Receptor Blockers, Antioxidant Inflammation Modulator, Calcium Channel Blockers, Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors), Renin Inhibitors, Others ); Diagnosis ( Imaging Tests, Renal Function Testing, Urine Test, Blood Test, Renal Biopsy ); End User ( Hospitals and Clinics, Ambulatory Surgical Centers, Diagnostic Centers, Research Institutes ), and Geography

Report Code: TIPRE00008011 | No. of Pages: 150 | Category: Pharmaceuticals | Status: Upcoming
Covid
MARKET INTRODUCTION

Diabetic nephropathy is a medical condition where the kidneys are damaged due to diabetes. High blood glucose levels damages the kidneys and allows the protein to enter the urine. Diabetic nephropathy can further lead to chronic kidney disease and kidney failure. Imaging, blood tests, urine tests are used to diagnose diabetic nephropathy.

MARKET DYNAMICS

Diabetic nephropathy market is anticipated to grow during the forecast period owing to increasing incidences of diabetes, shift to sedentary lifestyle, growing geriatric population and increased consumption of alcohol. Moreover, inorganic strategies by the market players like collaborations, mergers, and acquisitions by the market players are likely to create opportunities during the forecast period.

MARKET SCOPE

The "Global Diabetic nephropathy market analysis to 2027" is a specialized and in-depth study of the medical device industry with a special focus on the global market trend analysis. The report aims to provide an overview of diabetic nephropathy market with detailed market segmentation by indication, treatment type, indication, diagnosis, end user and geography. The global diabetic nephropathy market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading diabetic nephropathy market players and offers key trends and opportunities in the market.

MARKET SEGMENTATION

The global diabetic nephropathy market is segmented on the basis of indication, treatment type, indication, diagnosis, and end user. Based on indication, the market is segmented as type-1 diabetes, and type-2 diabetes. Based on treatment type, the market is segmented as diuretics, angiotensin receptor blockers, antioxidant inflammation modulator, calcium channel blockers, angiotensin-converting enzyme inhibitors (ace inhibitors), renin inhibitors, and others. Based on diagnosis the market is segmented into imaging tests, renal function testing, urine test, blood test, and renal biopsy. The end user segment is further divided into hospitals and clinics, ambulatory surgical centers, diagnostic centers, and research institutes.



Get more information on this report :

REGIONAL FRAMEWORK


The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global diabetic nephropathy market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The diabetic nephropathy market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting diabetic nephropathy market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trends. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the diabetic nephropathy market in these regions.



Get more information on this report :

MARKET PLAYERS


The report covers key developments in the diabetic nephropathy market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from diabetic nephropathy market are anticipated to lucrative growth opportunities in the future with the rising demand for diabetic nephropathy market in the global market. Below mentioned is the list of few companies engaged in the diabetic nephropathy market.

The report also includes the profiles of key diabetic nephropathy market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.

  •  ASTRAZENECA PLC
  •  BAYER AG
  •  NOVARTIS AG
  •  NOVO NORDISK AS
  •  MERCK AND CO., INC
  •  ALLERGAN, INC
  •  ABBOTT
  •  BOEHRINGER INGELHEIM GMBH
  •  ABBVIE INC
  •  PFIZER INC

The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.


Get more information on this report :

TABLE OF CONTENTS

1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Diabetic Nephropathy Market - By Indication
1.3.2 Diabetic Nephropathy Market - By Treatment Type
1.3.3 Diabetic Nephropathy Market - By Diagnosis
1.3.4 Diabetic Nephropathy Market - By End User
1.3.5 Diabetic Nephropathy Market - By Region
1.3.5.1 By Country

2. KEY TAKEAWAYS

3. RESEARCH METHODOLOGY

4. DIABETIC NEPHROPATHY MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS

5. DIABETIC NEPHROPATHY MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC

6. DIABETIC NEPHROPATHY MARKET - GLOBAL MARKET ANALYSIS
6.1. DIABETIC NEPHROPATHY - GLOBAL MARKET OVERVIEW
6.2. DIABETIC NEPHROPATHY - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE

7. DIABETIC NEPHROPATHY MARKET - REVENUE AND FORECASTS TO 2027 - INDICATION
7.1. OVERVIEW
7.2. INDICATION MARKET FORECASTS AND ANALYSIS
7.3. TYPE-1 DIABETES
7.3.1. Overview
7.3.2. Type-1 Diabetes Market Forecast and Analysis
7.4. TYPE-2 DIABETES
7.4.1. Overview
7.4.2. Type-2 Diabetes Market Forecast and Analysis

8. DIABETIC NEPHROPATHY MARKET - REVENUE AND FORECASTS TO 2027 - TREATMENT TYPE
8.1. OVERVIEW
8.2. TREATMENT TYPE MARKET FORECASTS AND ANALYSIS
8.3. DIURETICS
8.3.1. Overview
8.3.2. Diuretics Market Forecast and Analysis
8.4. ANGIOTENSIN RECEPTOR BLOCKERS
8.4.1. Overview
8.4.2. Angiotensin Receptor Blockers Market Forecast and Analysis
8.5. ANTIOXIDANT INFLAMMATION MODULATOR
8.5.1. Overview
8.5.2. Antioxidant Inflammation Modulator Market Forecast and Analysis
8.6. CALCIUM CHANNEL BLOCKERS
8.6.1. Overview
8.6.2. Calcium Channel Blockers Market Forecast and Analysis
8.7. ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)
8.7.1. Overview
8.7.2. Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors) Market Forecast and Analysis
8.8. RENIN INHIBITORS
8.8.1. Overview
8.8.2. Renin Inhibitors Market Forecast and Analysis
8.9. OTHERS
8.9.1. Overview
8.9.2. Others Market Forecast and Analysis

9. DIABETIC NEPHROPATHY MARKET - REVENUE AND FORECASTS TO 2027 - DIAGNOSIS
9.1. OVERVIEW
9.2. DIAGNOSIS MARKET FORECASTS AND ANALYSIS
9.3. IMAGING TESTS
9.3.1. Overview
9.3.2. Imaging Tests Market Forecast and Analysis
9.4. RENAL FUNCTION TESTING
9.4.1. Overview
9.4.2. Renal Function Testing Market Forecast and Analysis
9.5. URINE TEST
9.5.1. Overview
9.5.2. Urine Test Market Forecast and Analysis
9.6. BLOOD TEST
9.6.1. Overview
9.6.2. Blood Test Market Forecast and Analysis
9.7. RENAL BIOPSY
9.7.1. Overview
9.7.2. Renal Biopsy Market Forecast and Analysis

10. DIABETIC NEPHROPATHY MARKET - REVENUE AND FORECASTS TO 2027 - END USER
10.1. OVERVIEW
10.2. END USER MARKET FORECASTS AND ANALYSIS
10.3. HOSPITALS AND CLINICS
10.3.1. Overview
10.3.2. Hospitals and Clinics Market Forecast and Analysis
10.4. AMBULATORY SURGICAL CENTERS
10.4.1. Overview
10.4.2. Ambulatory Surgical Centers Market Forecast and Analysis
10.5. DIAGNOSTIC CENTERS
10.5.1. Overview
10.5.2. Diagnostic Centers Market Forecast and Analysis
10.6. RESEARCH INSTITUTES
10.6.1. Overview
10.6.2. Research Institutes Market Forecast and Analysis

11. DIABETIC NEPHROPATHY MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
11.1. NORTH AMERICA
11.1.1 North America Diabetic Nephropathy Market Overview
11.1.2 North America Diabetic Nephropathy Market Forecasts and Analysis
11.1.3 North America Diabetic Nephropathy Market Forecasts and Analysis - By Indication
11.1.4 North America Diabetic Nephropathy Market Forecasts and Analysis - By Treatment Type
11.1.5 North America Diabetic Nephropathy Market Forecasts and Analysis - By Diagnosis
11.1.6 North America Diabetic Nephropathy Market Forecasts and Analysis - By End User
11.1.7 North America Diabetic Nephropathy Market Forecasts and Analysis - By Countries
11.1.7.1 United States Diabetic Nephropathy Market
11.1.7.1.1 United States Diabetic Nephropathy Market by Indication
11.1.7.1.2 United States Diabetic Nephropathy Market by Treatment Type
11.1.7.1.3 United States Diabetic Nephropathy Market by Diagnosis
11.1.7.1.4 United States Diabetic Nephropathy Market by End User
11.1.7.2 Canada Diabetic Nephropathy Market
11.1.7.2.1 Canada Diabetic Nephropathy Market by Indication
11.1.7.2.2 Canada Diabetic Nephropathy Market by Treatment Type
11.1.7.2.3 Canada Diabetic Nephropathy Market by Diagnosis
11.1.7.2.4 Canada Diabetic Nephropathy Market by End User
11.1.7.3 Mexico Diabetic Nephropathy Market
11.1.7.3.1 Mexico Diabetic Nephropathy Market by Indication
11.1.7.3.2 Mexico Diabetic Nephropathy Market by Treatment Type
11.1.7.3.3 Mexico Diabetic Nephropathy Market by Diagnosis
11.1.7.3.4 Mexico Diabetic Nephropathy Market by End User
11.2. EUROPE
11.2.1 Europe Diabetic Nephropathy Market Overview
11.2.2 Europe Diabetic Nephropathy Market Forecasts and Analysis
11.2.3 Europe Diabetic Nephropathy Market Forecasts and Analysis - By Indication
11.2.4 Europe Diabetic Nephropathy Market Forecasts and Analysis - By Treatment Type
11.2.5 Europe Diabetic Nephropathy Market Forecasts and Analysis - By Diagnosis
11.2.6 Europe Diabetic Nephropathy Market Forecasts and Analysis - By End User
11.2.7 Europe Diabetic Nephropathy Market Forecasts and Analysis - By Countries
11.2.7.1 Germany Diabetic Nephropathy Market
11.2.7.1.1 Germany Diabetic Nephropathy Market by Indication
11.2.7.1.2 Germany Diabetic Nephropathy Market by Treatment Type
11.2.7.1.3 Germany Diabetic Nephropathy Market by Diagnosis
11.2.7.1.4 Germany Diabetic Nephropathy Market by End User
11.2.7.2 France Diabetic Nephropathy Market
11.2.7.2.1 France Diabetic Nephropathy Market by Indication
11.2.7.2.2 France Diabetic Nephropathy Market by Treatment Type
11.2.7.2.3 France Diabetic Nephropathy Market by Diagnosis
11.2.7.2.4 France Diabetic Nephropathy Market by End User
11.2.7.3 Italy Diabetic Nephropathy Market
11.2.7.3.1 Italy Diabetic Nephropathy Market by Indication
11.2.7.3.2 Italy Diabetic Nephropathy Market by Treatment Type
11.2.7.3.3 Italy Diabetic Nephropathy Market by Diagnosis
11.2.7.3.4 Italy Diabetic Nephropathy Market by End User
11.2.7.4 Spain Diabetic Nephropathy Market
11.2.7.4.1 Spain Diabetic Nephropathy Market by Indication
11.2.7.4.2 Spain Diabetic Nephropathy Market by Treatment Type
11.2.7.4.3 Spain Diabetic Nephropathy Market by Diagnosis
11.2.7.4.4 Spain Diabetic Nephropathy Market by End User
11.2.7.5 United Kingdom Diabetic Nephropathy Market
11.2.7.5.1 United Kingdom Diabetic Nephropathy Market by Indication
11.2.7.5.2 United Kingdom Diabetic Nephropathy Market by Treatment Type
11.2.7.5.3 United Kingdom Diabetic Nephropathy Market by Diagnosis
11.2.7.5.4 United Kingdom Diabetic Nephropathy Market by End User
11.3. ASIA-PACIFIC
11.3.1 Asia-Pacific Diabetic Nephropathy Market Overview
11.3.2 Asia-Pacific Diabetic Nephropathy Market Forecasts and Analysis
11.3.3 Asia-Pacific Diabetic Nephropathy Market Forecasts and Analysis - By Indication
11.3.4 Asia-Pacific Diabetic Nephropathy Market Forecasts and Analysis - By Treatment Type
11.3.5 Asia-Pacific Diabetic Nephropathy Market Forecasts and Analysis - By Diagnosis
11.3.6 Asia-Pacific Diabetic Nephropathy Market Forecasts and Analysis - By End User
11.3.7 Asia-Pacific Diabetic Nephropathy Market Forecasts and Analysis - By Countries
11.3.7.1 Australia Diabetic Nephropathy Market
11.3.7.1.1 Australia Diabetic Nephropathy Market by Indication
11.3.7.1.2 Australia Diabetic Nephropathy Market by Treatment Type
11.3.7.1.3 Australia Diabetic Nephropathy Market by Diagnosis
11.3.7.1.4 Australia Diabetic Nephropathy Market by End User
11.3.7.2 China Diabetic Nephropathy Market
11.3.7.2.1 China Diabetic Nephropathy Market by Indication
11.3.7.2.2 China Diabetic Nephropathy Market by Treatment Type
11.3.7.2.3 China Diabetic Nephropathy Market by Diagnosis
11.3.7.2.4 China Diabetic Nephropathy Market by End User
11.3.7.3 India Diabetic Nephropathy Market
11.3.7.3.1 India Diabetic Nephropathy Market by Indication
11.3.7.3.2 India Diabetic Nephropathy Market by Treatment Type
11.3.7.3.3 India Diabetic Nephropathy Market by Diagnosis
11.3.7.3.4 India Diabetic Nephropathy Market by End User
11.3.7.4 Japan Diabetic Nephropathy Market
11.3.7.4.1 Japan Diabetic Nephropathy Market by Indication
11.3.7.4.2 Japan Diabetic Nephropathy Market by Treatment Type
11.3.7.4.3 Japan Diabetic Nephropathy Market by Diagnosis
11.3.7.4.4 Japan Diabetic Nephropathy Market by End User
11.3.7.5 South Korea Diabetic Nephropathy Market
11.3.7.5.1 South Korea Diabetic Nephropathy Market by Indication
11.3.7.5.2 South Korea Diabetic Nephropathy Market by Treatment Type
11.3.7.5.3 South Korea Diabetic Nephropathy Market by Diagnosis
11.3.7.5.4 South Korea Diabetic Nephropathy Market by End User
11.4. MIDDLE EAST AND AFRICA
11.4.1 Middle East and Africa Diabetic Nephropathy Market Overview
11.4.2 Middle East and Africa Diabetic Nephropathy Market Forecasts and Analysis
11.4.3 Middle East and Africa Diabetic Nephropathy Market Forecasts and Analysis - By Indication
11.4.4 Middle East and Africa Diabetic Nephropathy Market Forecasts and Analysis - By Treatment Type
11.4.5 Middle East and Africa Diabetic Nephropathy Market Forecasts and Analysis - By Diagnosis
11.4.6 Middle East and Africa Diabetic Nephropathy Market Forecasts and Analysis - By End User
11.4.7 Middle East and Africa Diabetic Nephropathy Market Forecasts and Analysis - By Countries
11.4.7.1 South Africa Diabetic Nephropathy Market
11.4.7.1.1 South Africa Diabetic Nephropathy Market by Indication
11.4.7.1.2 South Africa Diabetic Nephropathy Market by Treatment Type
11.4.7.1.3 South Africa Diabetic Nephropathy Market by Diagnosis
11.4.7.1.4 South Africa Diabetic Nephropathy Market by End User
11.4.7.2 Saudi Arabia Diabetic Nephropathy Market
11.4.7.2.1 Saudi Arabia Diabetic Nephropathy Market by Indication
11.4.7.2.2 Saudi Arabia Diabetic Nephropathy Market by Treatment Type
11.4.7.2.3 Saudi Arabia Diabetic Nephropathy Market by Diagnosis
11.4.7.2.4 Saudi Arabia Diabetic Nephropathy Market by End User
11.4.7.3 U.A.E Diabetic Nephropathy Market
11.4.7.3.1 U.A.E Diabetic Nephropathy Market by Indication
11.4.7.3.2 U.A.E Diabetic Nephropathy Market by Treatment Type
11.4.7.3.3 U.A.E Diabetic Nephropathy Market by Diagnosis
11.4.7.3.4 U.A.E Diabetic Nephropathy Market by End User
11.5. SOUTH AND CENTRAL AMERICA
11.5.1 South and Central America Diabetic Nephropathy Market Overview
11.5.2 South and Central America Diabetic Nephropathy Market Forecasts and Analysis
11.5.3 South and Central America Diabetic Nephropathy Market Forecasts and Analysis - By Indication
11.5.4 South and Central America Diabetic Nephropathy Market Forecasts and Analysis - By Treatment Type
11.5.5 South and Central America Diabetic Nephropathy Market Forecasts and Analysis - By Diagnosis
11.5.6 South and Central America Diabetic Nephropathy Market Forecasts and Analysis - By End User
11.5.7 South and Central America Diabetic Nephropathy Market Forecasts and Analysis - By Countries
11.5.7.1 Brazil Diabetic Nephropathy Market
11.5.7.1.1 Brazil Diabetic Nephropathy Market by Indication
11.5.7.1.2 Brazil Diabetic Nephropathy Market by Treatment Type
11.5.7.1.3 Brazil Diabetic Nephropathy Market by Diagnosis
11.5.7.1.4 Brazil Diabetic Nephropathy Market by End User
11.5.7.2 Argentina Diabetic Nephropathy Market
11.5.7.2.1 Argentina Diabetic Nephropathy Market by Indication
11.5.7.2.2 Argentina Diabetic Nephropathy Market by Treatment Type
11.5.7.2.3 Argentina Diabetic Nephropathy Market by Diagnosis
11.5.7.2.4 Argentina Diabetic Nephropathy Market by End User

12. INDUSTRY LANDSCAPE
12.1. MERGERS AND ACQUISITIONS
12.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
12.3. NEW PRODUCT LAUNCHES
12.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS

13. DIABETIC NEPHROPATHY MARKET, KEY COMPANY PROFILES
13.1. ASTRAZENECA PLC
13.1.1. Key Facts
13.1.2. Business Description
13.1.3. Products and Services
13.1.4. Financial Overview
13.1.5. SWOT Analysis
13.1.6. Key Developments
13.2. BAYER AG
13.2.1. Key Facts
13.2.2. Business Description
13.2.3. Products and Services
13.2.4. Financial Overview
13.2.5. SWOT Analysis
13.2.6. Key Developments
13.3. NOVARTIS AG
13.3.1. Key Facts
13.3.2. Business Description
13.3.3. Products and Services
13.3.4. Financial Overview
13.3.5. SWOT Analysis
13.3.6. Key Developments
13.4. NOVO NORDISK AS
13.4.1. Key Facts
13.4.2. Business Description
13.4.3. Products and Services
13.4.4. Financial Overview
13.4.5. SWOT Analysis
13.4.6. Key Developments
13.5. MERCK AND CO., INC.
13.5.1. Key Facts
13.5.2. Business Description
13.5.3. Products and Services
13.5.4. Financial Overview
13.5.5. SWOT Analysis
13.5.6. Key Developments
13.6. ALLERGAN, INC.
13.6.1. Key Facts
13.6.2. Business Description
13.6.3. Products and Services
13.6.4. Financial Overview
13.6.5. SWOT Analysis
13.6.6. Key Developments
13.7. ABBOTT LABORATORIES
13.7.1. Key Facts
13.7.2. Business Description
13.7.3. Products and Services
13.7.4. Financial Overview
13.7.5. SWOT Analysis
13.7.6. Key Developments
13.8. BOEHRINGER INGELHEIM GMBH
13.8.1. Key Facts
13.8.2. Business Description
13.8.3. Products and Services
13.8.4. Financial Overview
13.8.5. SWOT Analysis
13.8.6. Key Developments
13.9. ABBVIE INC.
13.9.1. Key Facts
13.9.2. Business Description
13.9.3. Products and Services
13.9.4. Financial Overview
13.9.5. SWOT Analysis
13.9.6. Key Developments
13.10. PFIZER INC.
13.10.1. Key Facts
13.10.2. Business Description
13.10.3. Products and Services
13.10.4. Financial Overview
13.10.5. SWOT Analysis
13.10.6. Key Developments
14. APPENDIX
14.1. ABOUT THE INSIGHT PARTNERS
14.2. GLOSSARY OF TERMS
The List of Companies

1. ASTRAZENECA PLC
2. BAYER AG
3. NOVARTIS AG
4. NOVO NORDISK AS
5. MERCK AND CO., INC
6. ALLERGAN, INC
7. ABBOTT
8. BOEHRINGER INGELHEIM GMBH
9. ABBVIE INC
10. PFIZER INC
TIPRE00008011
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing

Free

20%

customization on Pre-Booking